Animal models of inflammatory and autoimmune disorders as asthma, rheumatoid arthritis, multiple sclerosis, and type 2 diabetes associated nephropathy [24, 25, 33], has highlighted the efficacy of treatment with PPAR-γ agonists in improving several signs associated with these diseases. This evidence concerns the gene PPARG and rheumatoid arthritis.